Introduction: The prognostic value of the modified Glasgow Prognostic Score (mGPS), a systemic inflammatory response marker, has been reported in various cancers. However, its role in patients with metastatic colorectal cancer (mCRC) undergoing first-line FOLFOXIRI + bevacizumab (BV) therapy remains unclear. In this study, we aimed to evaluate the prognostic significance of pretreatment mGPS and other inflammatory markers in this patient population.
Methods: This study retrospectively reviewed 133 patients with mCRC treated with first-line FOLFOXIRI + BV. We assessed the prognostic value of pretreatment mGPS and other inflammatory markers (neutrophil-to-lymphocyte, platelet-to-lymphocyte, and lymphocyte-to-monocyte ratios) in relation to progression-free survival (PFS) and overall survival (OS).
Results: Higher mGPS (score 2) was significantly associated with poor PFS and OS. Multivariate analysis identified mGPS 2 as an independent predictor of worse PFS (hazard ratio: 2.76, p = 0.004) and OS (hazard ratio: 3.43, p < 0.001). No significant associations were found between other inflammatory markers and survival outcomes.
Conclusions: Pretreatment mGPS is a simple and useful prognostic factor for mCRC patients receiving FOLFOXIRI + BV therapy and may serve as a convenient indicator for accurate prognosis prediction and treatment decision-making.
Keywords: Colorectal cancer; FOLFOXIRI; Modified Glasgow Prognostic Score; Prognostic factor.
© 2025 S. Karger AG, Basel.